Glenmark Pharmaceuticals · NSE: GLENMARK · BSE: 532296
Q4 FY21 results · Jan–Mar 2021
Glenmark Pharmaceuticals reported revenue from operations of ₹2,859.90 crore (up 3.3% from Q4 FY20) and net profit of ₹233.87 crore (up 6.2% from Q4 FY20) for Q4 FY21 (Jan–Mar 2021), on a consolidated basis.
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,859.90 | 2,767.49 | +3.3% | 2,786.76 | +2.6% |
| Other income | 8.49 | 44.15 | −80.8% | 15.09 | −43.7% |
| Total income | 2,868.39 | 2,811.63 | +2.0% | 2,801.85 | +2.4% |
| Profit before tax | 337.51 | 317.96 | +6.2% | 347.97 | −3.0% |
| Net profit for the period | 233.87 | 220.31 | +6.2% | 248.18 | −5.8% |
| EPS, basic (₹) | 8.29 | 7.81 | +6.1% | 8.80 | −5.8% |
| Net margin (%) | 8.2 | 8.0 | 8.9 |
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,850.37 | 1,607.73 | +15.1% | 1,972.48 | −6.2% |
| Other income | 116.86 | 251.29 | −53.5% | 81.13 | +44.0% |
| Total income | 1,967.23 | 1,859.02 | +5.8% | 2,053.61 | −4.2% |
| Profit before tax | 373.36 | 372.55 | +0.2% | 533.01 | −30.0% |
| Net profit for the period | 341.77 | 349.19 | −2.1% | 442.32 | −22.7% |
| EPS, basic (₹) | 12.11 | 12.38 | −2.2% | 15.68 | −22.8% |
| Net margin (%) | 18.5 | 21.7 | 22.4 |
Consolidated
- Filed with BSE
- 31 May 2021, 08:37 IST
- Board meeting
- 28 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 31 May 2021, 08:37 IST
- Board meeting
- 28 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE